Molecular Templates, Inc.

How big is Molecular Templates, Inc.?

As of Jun 18, Molecular Templates, Inc. has a market capitalization of 0.00, classifying it as a Micro Cap company, with net sales of 25.48 million and a net profit of -15.63 million over the last four quarters. The company's shareholder's funds are 4.21 million, and total assets are 35.38 million as of Dec 23.

Market Cap: As of Jun 18, Molecular Templates, Inc. has a market capitalization of 0.00, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 25.48 million and a net profit of -15.63 million.<BR><BR>Balance Sheet Snapshot: As of Dec 23, the company's shareholder's funds amounted to 4.21 million, while total assets were reported at 35.38 million.

Should I buy, sell or hold Molecular Templates, Inc.?

Who are in the management team of Molecular Templates, Inc.?

As of March 2022, the management team of Molecular Templates, Inc. includes Dr. Harold Selick (Chairman), Dr. Eric Poma (CEO and CSO), and several independent directors: Dr. David Hirsch, Mr. David Hoffmann, Mr. Kevin Lalande, Mr. Jonathan Lanfear, and Mr. Scott Morenstein. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Molecular Templates, Inc. includes the following individuals:<BR><BR>- Dr. Harold Selick, Chairman of the Board<BR>- Dr. Eric Poma, Chief Executive Officer, Chief Scientific Officer, and Director<BR>- Dr. David Hirsch, Independent Director<BR>- Mr. David Hoffmann, Independent Director<BR>- Mr. Kevin Lalande, Independent Director<BR>- Mr. Jonathan Lanfear, Independent Director<BR>- Mr. Scott Morenstein, Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Is Molecular Templates, Inc. overvalued or undervalued?

As of March 28, 2018, Molecular Templates, Inc. is considered risky and overvalued due to a P/E ratio of 0.00, an EV to EBITDA ratio of 0.51, a -259.19% ROE, and a year-to-date stock return of -99.75%, significantly underperforming compared to its peers and the S&P 500.

As of 28 March 2018, the valuation grade for Molecular Templates, Inc. has moved from does not qualify to risky, indicating significant concerns about the company's financial health. The company appears to be overvalued given its current situation, particularly highlighted by a P/E ratio of 0.00 and an EV to EBITDA ratio of 0.51, which suggests that the market is not assigning any value to its earnings potential. Additionally, the ROE stands at a staggering -259.19%, reflecting severe losses relative to shareholder equity.<BR><BR>In comparison to its peers, Molecular Templates, Inc. is positioned unfavorably against companies like Precision BioSciences, Inc., which has a P/E of -1.4199 and an EV to EBITDA of -0.1189, and LAVA Therapeutics NV, with a P/E of -1.0316 and an EV to EBITDA of 0.9262. These comparisons further underscore the risks associated with investing in Molecular Templates, Inc. The company's stock has drastically underperformed, with a year-to-date return of -99.75% compared to a modest 2.44% return for the S&P 500, reinforcing the view that it is overvalued in the current market context.

Is Molecular Templates, Inc. technically bullish or bearish?

As of February 10, 2025, Molecular Templates, Inc. shows a mildly bearish technical trend, with mixed signals from MACD and moving averages, and a significant underperformance of -99.75% year-to-date compared to the S&P 500's 12.22%.

As of 10 February 2025, the technical trend for Molecular Templates, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD also indicates a mildly bullish stance. However, the daily moving averages are mildly bearish, and the Bollinger Bands show a sideways trend on the weekly and mildly bearish on the monthly. The KST presents a mixed view with a mildly bullish weekly signal but a bearish monthly signal. There is no clear trend indicated by Dow Theory or OBV.<BR><BR>The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -99.75% against the benchmark's 12.22%, and a one-year return of -99.99% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by the mixed signals from moving averages and Bollinger Bands.